Fig. 1: Overview of the correlation analyses of miRNAs in the T1219 study.

a The T1219 study was a single-arm phase II trial to administer biweekly nivolumab in combination with gemcitabine and S-1 as the first-line treatment in advanced BTC. The parallel plasma samples of pre- and post-treatment after 6 weeks were collected from 46 patients. b Plasma samples were subjected to circulating miRNA extraction, reverse transcription, and miRNA profile analyses.